Manager TitleAgeSince
Chief Executive Officer 58 27/08/2014
Comptroller/Controller/Auditor 62 21/03/2019
Director TitleAgeSince
Director/Board Member 58 27/08/2014
Director/Board Member 73 30/03/2023
Director/Board Member 40 28/03/2024
Change 5-day change 1-year change 3-year change Capi.($)
-30.43%-75.38% - - 400K
-3.00%+0.33%+77.39%+109.41% 73.96B
+1.90%+23.53%+56.60%+97.76% 64.66B
+0.55%+1.64%-5.15%+471.68% 27.32B
+5.12%+25.22%+5.24%-0.82% 27.86B
+2.74%+12.98%+62.84%+28.14% 25.97B
+0.47%+6.12%+36.66%-13.79% 19.98B
+1.82%-6.67%+247.46%+393.10% 17.84B
+0.94%+3.36%+18.55%+532.94% 16.24B
+0.73%+5.54%+39.71%+153.07% 13.3B
Average -1.92%+7.62%+59.92%+196.83% 31.9B
Weighted average by Cap. +0.68%+8.75%+59.20%+158.24%
Logo Cellivery Therapeutics, Inc.
Cellivery Therapeutics, Inc. is a Korea-based company principally engaged in the research and development of medicines and biotherapeutics. The Company develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The Company research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).
Employees
-
  1. Stock Market
  2. Stocks
  3. A268600 Stock